Ratings by Raymond James (Dane Leone)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/19/2021 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 6/29/2021 | Tarsus Pharmaceuticals | TARS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/26/2021 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2021 | Xencor, Inc. | XNCR | Upgrade | Outperform (Market Perform) |
48.35 (30.78) |
-36.34% | Details | |
| 2/19/2021 | Galapagos NV | GLPG | Upgrade | Outperform (Market Perform) |
83.80 (60.54) |
-27.76% | Details | |
| 2/16/2021 | G1 Therapeutics | GTHX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2021 | Regenxbio Inc. | RGNX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/2/2021 | Sage Therapeutics | SAGE | New Coverage | Market Perform (N/A) |
80.65 (43.73) |
-45.78% | Details | |
| 1/6/2021 | Regenxbio Inc. | RGNX | Upgrade | Strong Buy (Outperform) |
44.91 (32.32) |
-28.03% | Details | |
| 11/30/2020 | Sage Therapeutics | SAGE | Downgrade | Market Perform (Outperform) |
75.57 (43.73) |
-42.13% | Details | |
| 11/17/2020 | G1 Therapeutics | GTHX | Downgrade | Outperform (Strong Buy) |
13.19 (17.31) |
31.24% | Details | |
| 11/13/2020 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/12/2020 | Adverum Biotechnologies | ADVM | Upgrade | Market Perform (Underperform) |
13.37 (2.27) |
-83.02% | Details | |
| 11/10/2020 | Tarsus Pharmaceuticals | TARS | New Coverage | Strong Buy (N/A) |
23.19 (22.57) |
-2.67% | Details | |
| 10/26/2020 | Amgen | AMGN | Upgrade | Outperform (Market Perform) |
227.98 (241.54) |
5.95% | Details | |
| 10/16/2020 | Blueprint Medicines | BPMC | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/16/2020 | Simulations Plus | SLP | New Coverage | Outperform (N/A) |
71.90 (47.19) |
-34.37% | Details | |
| 10/8/2020 | Cytokinetics | CYTK | Downgrade | Outperform (Strong Buy) |
27.66 (29.68) |
7.3% | Details | |
| 10/8/2020 | Amgen | AMGN | Downgrade | Market Perform (Outperform) |
257.67 (241.54) |
-6.26% | Details | |
| 9/22/2020 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 9/21/2020 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2020 | Sage Therapeutics | SAGE | Upgrade | Outperform (Market Perform) |
50.70 (75.57) |
49.05% | Details | |
| 7/28/2020 | Bristol-Myers Squibb Co. | BMY | New Coverage | Outperform (N/A) |
57.85 (67.87) |
17.32% | Details | |
| 7/14/2020 | Blueprint Medicines | BPMC | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/10/2020 | Cytokinetics | CYTK | New Coverage | Strong Buy (N/A) |
26.92 (27.66) |
2.75% | Details | |
| 6/26/2020 | Adverum Biotechnologies | ADVM | Downgrade | Underperform (Market Perform) |
23.32 (13.37) |
-42.67% | Details | |
| 6/11/2020 | Magenta Therapeutics | MGTA | Maintain | Outperform (N/A) |
|
Details | ||
| 6/10/2020 | Ayala Pharmaceuticals | AYLA | New Coverage | Outperform (N/A) |
15.16 (12.50) |
-17.55% | Details | |
| 6/1/2020 | Allogene | ALLO | Downgrade | Market Perform (Outperform) |
46.54 (21.95) |
-52.84% | Details | |
| 4/28/2020 | Blueprint Medicines | BPMC | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/30/2020 | Amgen | AMGN | Upgrade | Outperform (Market Perform) |
198.49 (257.67) |
29.82% | Details | |
| 3/3/2020 | Ocular Therapeutix | OCUL | Upgrade | Strong Buy (Outperform) |
4.69 (11.01) |
134.75% | Details | |
| 2/20/2020 | bluebird bio | BLUE | Downgrade | Market Perform (Strong Buy) |
88.22 (25.43) |
-71.17% | Details | |
| 2/19/2020 | bluebird bio | BLUE | Downgrade | Market Perform (Strong Buy) |
88.22 (25.43) |
-71.17% | Details | |
| 2/10/2020 | Ocular Therapeutix | OCUL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2020 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/24/2019 | Regeneron Pharma | REGN | New Coverage | Market Perform (N/A) |
375.62 (574.61) |
52.98% | Details | |
| 12/24/2019 | Amgen | AMGN | New Coverage | Market Perform (N/A) |
243.06 (198.49) |
-18.34% | Details | |
| 11/5/2019 | Blueprint Medicines | BPMC | Upgrade | Strong Buy (Outperform) |
67.12 (87.87) |
30.91% | Details | |
| 9/11/2019 | Blueprint Medicines | BPMC | Upgrade | Outperform (Market Perform) |
72.90 (67.12) |
-7.93% | Details | |
| 8/15/2019 | Blueprint Medicines | BPMC | New Coverage | Market Perform (N/A) |
85.76 (72.90) |
-15% | Details | |
| 8/7/2019 | Xencor, Inc. | XNCR | Downgrade | Market Perform (Outperform) |
46.27 (48.35) |
4.5% | Details | |
| 7/26/2019 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
28.12 (53.45) |
90.08% | Details | |
| 7/15/2019 | Galapagos NV | GLPG | Downgrade | Market Perform (Strong Buy) |
145.75 (83.80) |
-42.5% | Details | |
| 6/14/2019 | BioTime, Inc. | BTX | New Coverage | Market Perform (N/A) |
1.00 (11.49) |
1049% | Details | |
| 6/14/2019 | Regenxbio Inc. | RGNX | New Coverage | Outperform (N/A) |
46.85 (32.32) |
-31.01% | Details | |
| 6/14/2019 | Adverum Biotechnologies | ADVM | New Coverage | Market Perform (N/A) |
11.06 (23.32) |
110.85% | Details | |
| 5/21/2019 | Ocular Therapeutix | OCUL | Downgrade | Outperform (Strong Buy) |
3.37 (4.69) |
39.17% | Details | |
| 3/15/2019 | Xencor, Inc. | XNCR | New Coverage | Outperform (N/A) |
29.28 (46.27) |
58.03% | Details | |
| 3/15/2019 | Magenta Therapeutics | MGTA | New Coverage | Outperform (N/A) |
14.27 (7.12) |
-50.11% | Details | |
| 3/15/2019 | Gritstone Oncology | GRTS | New Coverage | Outperform (N/A) |
10.74 (6.68) |
-37.8% | Details | |
| 3/14/2019 | Allogene | ALLO | New Coverage | Outperform (N/A) |
26.89 (46.54) |
73.08% | Details | |
| 3/8/2019 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/7/2019 | Loxo Oncology | LOXO | Downgrade | Market Perform (Strong Buy) |
139.87 (234.80) |
67.87% | Details | |
| 12/3/2018 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/15/2018 | Ocular Therapeutix | OCUL | New Coverage | Strong Buy (N/A) |
5.29 (3.37) |
-36.29% | Details | |
| 11/15/2018 | Loxo Oncology | LOXO | New Coverage | Strong Buy (N/A) |
159.08 (139.87) |
-12.08% | Details | |
| 11/15/2018 | Galapagos NV | GLPG | New Coverage | Strong Buy (N/A) |
102.79 (145.75) |
41.79% | Details |
